Home › Companies › BMEA

Biomea Fusion

Market cap $35.5M 72.7M shares (10-Q, Oct 29, 2026) × $0.488 close Nov 17, 2026

Most recent annual filing: 2026-03-24

Catalyst timeline

4 trackedQuarter catalyst calendar →
  1. Icovamenib topline1Q 2027Icovamenib topline, 1Q 2027, thesis-defining
  2. Icovamenib COVALENT-211 topline1Q 2027Icovamenib COVALENT-211 topline, 1Q 2027, thesis-defining
  3. Biomea Fusion corporate financing1Q 2027Biomea Fusion corporate financing, 1Q 2027, routine
  4. Icovamenib COVALENT-212 topline2Q 2027Icovamenib COVALENT-212 topline, 2Q 2027, major

Bar width shows how precise the guidance is — a pin is a stated date, a wide band a six-month window. Deeper blue means more of the thesis rides on the event; it is not a view on the stock.

Pipeline (4 active programs)

Discontinued (1)

Capital (as filed)

Cash
$26.4M cash and cash equivalents · Sep 30, 2026 (10-Q)
Operating cash flow
−$8.4M quarter Jun 30, 2026 → Sep 30, 2026, year-to-date difference (10-Q)
As stated in coverage
$26.8M cash, runway into the second quarter of 2027 per the update of Nov 10, 2026 — the company's own words as read there, not the filed figure

Offering documents (1)

Cash, investments and operating cash flow are the company's own XBRL facts as filed with the SEC, each shown with its period end and tag. As-stated figures come from the company's own words as read in Biotech Distilled coverage, dated, and routinely count securities and planned financing that a balance sheet does not. Offering rows are the SEC cover pages as filed. Not investment advice. Figures as of Nov 18, 2026.

Biotech Distilled coverage (10)

Articles open on Substack. Some are subscriber-only; those marked ★ Distilled Pro are for Distilled Pro members.

Verdict history (10 calls)

Every verdict Biotech Distilled has published on Biomea Fusion, oldest first — the full history, never a selection. How calls are scored: the track record.

  1. Watch Biomea Fusion (BMEA) - Scientific Deep Dive for Icovamenib and Pipeline Products Compelling menin-inhibition science and oral GLP-1 pipeline are offset by a going-concern balance sheet and near-certain dilutive raise, warranting a wait-for-the-raise stance.
  2. Speculative buy speculative UPDATE: Biomea Fusion (BMEA) - The Zombie Trial Wakes Up COVALENT-112 T1D data showed durable C-peptide increases in two indications, widening icovamenib's optionality, though the balance sheet remains terrifying and a dilutive raise is still the base case.
  3. Speculative buy speculative UPDATE: Biomea Fusion (BMEA) - The ADA Receipts and the Quiet Catalyst Slip ADA data de-risked liver safety and confirmed a 1.8% placebo-adjusted HbA1c receipt in GLP-1 non-responders, but BMF-650 slipped to Q3 and the liquidity event likely precedes the data catalyst.
  4. Speculative buy speculative UPDATE: Biomea Fusion (BMEA) - The Catalysts Moved Past the Cash Both Phase IIb T2D readouts slipped into 2027 while cash runs out in the same quarter as the first readout, making this a downgrade on timing and financing sequencing rather than biology.
  5. Speculative buy speculative UPDATE: Biomea Fusion (BMEA) - "Near Completion" Became "Completed" COVALENT-211 fully enrolled at n=64 with a placebo-controlled design and Q1 2027 date now operationally supported, but financing sequencing and going-concern remain unchanged.
  6. Speculative buy speculative UPDATE: Biomea Fusion (BMEA) - The Raise Landed Before the Data The underwritten offering launched ahead of BMF-650 data with a demand-constrained structure, but the science and COVALENT-211 readout are unchanged; the pricing print is what matters.
  7. Watch UPDATE: Biomea Fusion (BMEA) - The Raise That Didn't Land The offering was terminated with no shares sold, leaving the going-concern gap open and now public, with all weight on the October BMF-650 print to enable a better-priced raise.
  8. Watch UPDATE: Biomea Fusion (BMEA) - The Financing Print Came Back Quiet BMF-650 Phase 1 showed clean tolerability but only 1.5–3.2% outpatient weight loss at or below the class benchmark, failing to reopen the financing window; icovamenib thesis intact but standing aside until a raise is priced.
  9. Avoid UPDATE: Biomea Fusion (BMEA) - The Deck Said the Quiet Part The BMF-650 slide deck revealed suspected dosing non-compliance in the top-dose cohort, weakening the licensing pitch; stock fell below $1 with a going-concern warning and no partner, making the next raise very expensive.
  10. Avoid UPDATE: Biomea Fusion (BMEA) - Q3 Status Check: The Runway Held, the Price Didn't Q3 10-Q kept runway into Q2 2027 on $26.8M cash but no financing or license was priced, stockholders' equity collapsed to $7.6M, and the stock sub-$1 means any raise is severely dilutive.

Every verdict Biotech Distilled has published on this company, in order, with the post it came from — the full history, never a selection. Position figures are the same ones shown on /track-record, computed by the same method. Editorial opinion, not investment advice.

Timing, in the company's words (7 quotes from 6 filings)

Sentences quoted verbatim from the company's SEC filings, newest filing first. Each sits under the filing it appeared in; the "matched to" tag names the calendar row it was read for.

Timing sentences quoted from the company's own SEC filings, each under the filing it appeared in. The 'matched to' tag is the calendar row the sentence was read for; the filing is the source. Not investment advice.

Filings & releases (29)

SEC filings from EDGAR and press releases captured from the company's investor-relations site, newest first. Releases captured from May 5, 2026; filings from March 2026. Summaries come from the BD update that read the document; "BD extracted" counts point at the pipeline table above. All companies →

1 more filing (13G holder notices, S-8, proxy material, SEC correspondence …)